TrialNature communications2026

NALIRIFOX versus gemcitabine plus nab-paclitaxel in Chinese patients with advanced pancreatic adenocarcinoma: a randomized, open-label phase II trial.

Chuntao Gao et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.